ERIS Lifesciences Ltd, engaged in the manufacturing and marketing of pharmaceutical products, reported robust financial results for Q2FY26. Financial Highlights: Revenues increased
(ERIS)
XNSE:ERIS, XBOM:ERIS
ERIS Lifesciences Q1 FY26 Earnings Results
ERIS Lifesciences Limited is engaged in the manufacture and marketing of pharmaceutical products. Presenting below are its Q1 FY26 Earnings Results. Q1
ERIS Lifesciences Ltd Q4FY25; 28% rise in Profits
ERIS Lifesciences Ltd is engaged in the business of manufacture and marketing of pharmaceutical products. Financial Results: ERIS Lifesciences Ltd reported Revenues
ERIS Lifesciences Ltd Q3FY25; 14% fall in Profits
ERIS Lifesciences Ltd is engaged in the business of manufacture and marketing of pharmaceutical products. Financial Results: ERIS Lifesciences Ltd reported Revenues
ERIS Lifesciences Ltd Q2FY25; 21% fall in Profits
ERIS Lifesciences Ltd is engaged in the business of manufacture and marketing of pharmaceutical products. Financial Results: ERIS Lifesciences Ltd reported Revenues
ERIS Lifesciences Ltd Q4FY24; 31% rise in Profits
ERIS Lifesciences Ltd is engaged in the business of manufacture and marketing of pharmaceutical products. Financial Results: ERIS Lifesciences Ltd reported Revenues
ERIS Lifesciences Ltd Q3FY24; 1% rise in Profits
ERIS Lifesciences Ltd is engaged in the business of manufacture and marketing of pharmaceutical products. Financial Results: ERIS Lifesciences Ltd reported Revenues
ERIS Lifesciences Ltd Q2FY24; 3% rise in Profits
ERIS Lifesciences Ltd is engaged in the business of manufacture and marketing of pharmaceutical products. Financial Results: ERIS Lifesciences Ltd reported Revenues
ERIS Lifesciences Ltd Q1FY24; 1% rise in Profits
ERIS Lifesciences Ltd is engaged in the business of manufacture and marketing of pharmaceutical products. Financial Results: ERIS Lifesciences Ltd reported Revenues
Eris Lifesciences Ltd (ERIS) Q2 FY23 Earnings Concall Transcript
Eris Lifesciences Ltd (NSE:ERIS) Q2 FY23 Earnings Concall dated Oct. 20, 2022 Corporate Participants: Krishnakumar Vaidyanathan -- Executive Director and Chief Operating